Literature DB >> 1722946

Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS.

R R Brown1, Y Ozaki, S P Datta, E C Borden, P M Sondel, D G Malone.   

Abstract

Tryptophan (Trp) is an indispensable amino acid required for biosynthesis of proteins, serotonin and niacin. Indoleamine 2,3-dioxygenase (IDO) is induced by infections, viruses, lipopolysaccharides, or interferons (IFNs) and this results in significant catabolism of Trp along the kynurenine (Kyn) pathway. Intracellular growth of Toxoplasma gondii and Chlamydia psittaci in human fibroblasts in vitro is inhibited by IFN-gamma and this inhibition is negated by extra Trp in the medium. Similarly, growth of a number of human cell lines in vitro is inhibited by IFN-gamma and addition of extra Trp restores growth. Thus, in some in vitro systems, antiproliferative effects of IFN-gamma are mediated by induced depletion of Trp. We find that cancer patients given Type I or Type II IFNs can induce IDO which results in decreased serum Trp levels (20-50% of pretreatment) and increased urinary metabolites of the Kyn pathway (5 to 500 fold of pretreatment). We speculate that in vivo antineoplastic effects of IFNs and clinical side effects are mediated, at least in part, by a general or localized depletion of Trp. In view of reported increases of IFNs in autoimmune diseases and our earlier findings of elevated urinary Trp metabolites in autoimmune diseases, it seems likely that systemic or local depletion of Trp occurs in autoimmune diseases and may relate to degeneration, wasting and other symptoms in such diseases. We find high levels of IDO in cells isolated from synovia of arthritic joints. IFNs are also elevated in human immunodeficiency virus (HIV) patients and increasing IFN levels are associated with a worsening prognosis. We propose that IDO is induced chronically by HIV infection, is further increased by opportunistic infections, and that this chronic loss of Trp initiates mechanisms responsible for the cachexia, dementia, diarrhea and possibly immunosuppression of AIDS patients. In these symptoms, AIDS resembles classical pellagra due to dietary deficiency of Trp and niacin. In preliminary studies, others report low levels of Trp and serotonin, and elevated levels of Kyn and quinolinic acid in AIDS patients. The implications of these data in cancer, autoimmune diseases and AIDS are discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1722946     DOI: 10.1007/978-1-4684-5952-4_39

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  30 in total

1.  Maternal tryptophan and kynurenine pathway metabolites and risk of preeclampsia.

Authors:  Roy M Nilsen; Anne-Lise Bjørke-Monsen; Oivind Midttun; Ottar Nygård; Eva R Pedersen; Arve Ulvik; Per Magnus; Håkon K Gjessing; Stein Emil Vollset; Per Magne Ueland
Journal:  Obstet Gynecol       Date:  2012-06       Impact factor: 7.661

Review 2.  NAD+ metabolism and oxidative stress: the golden nucleotide on a crown of thorns.

Authors:  Hassina Massudi; Ross Grant; Gilles J Guillemin; Nady Braidy
Journal:  Redox Rep       Date:  2012       Impact factor: 4.412

3.  Kynurenine and uric acid levels in chronic myeloid leukemia patients.

Authors:  Vladimir Vonka; Zuzana Humlova; Hana Klamova; Lenka Kujovska-Krcmova; Martina Petrackova; Eva Hamsikova; Monika Krmencikova-Fliegl; Martina Duskova; Zdenek Roth
Journal:  Oncoimmunology       Date:  2015-03-25       Impact factor: 8.110

4.  IDO1 and TGF-β Mediate Protective Effects of IFN-α in Antigen-Induced Arthritis.

Authors:  Jaya Prakash Chalise; Maria Teresa Pallotta; Sudeep Chenna Narendra; Björn Carlsson; Alberta Iacono; Joanitah Namale; Louis Boon; Ursula Grohmann; Mattias Magnusson
Journal:  J Immunol       Date:  2016-09-19       Impact factor: 5.422

5.  Kynurenine pathway metabolites in humans: disease and healthy States.

Authors:  Yiquan Chen; Gilles J Guillemin
Journal:  Int J Tryptophan Res       Date:  2009-01-08

Review 6.  Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management.

Authors:  Jennifer M Loftis; Annette M Matthews; Peter Hauser
Journal:  Drugs       Date:  2006       Impact factor: 9.546

7.  Diminished quality of life in patients with cancer correlates with tryptophan degradation.

Authors:  Katharina Schroecksnadel; Michael Fiegl; Karin Prassl; Christiana Winkler; Hubert A Denz; Dietmar Fuchs
Journal:  J Cancer Res Clin Oncol       Date:  2007-03-14       Impact factor: 4.553

8.  Mouse pancreatic islets are resistant to indoleamine 2,3 dioxygenase-induced general control nonderepressible-2 kinase stress pathway and maintain normal viability and function.

Authors:  Reza B Jalili; Farshad Forouzandeh; Alireza Moeenrezakhanlou; Gina R Rayat; Ray V Rajotte; Hasan Uludag; Aziz Ghahary
Journal:  Am J Pathol       Date:  2008-12-12       Impact factor: 4.307

Review 9.  Is IDO a key enzyme bridging the gap between tumor escape and tolerance induction?

Authors:  Stefan Löb; Alfred Königsrainer
Journal:  Langenbecks Arch Surg       Date:  2007-12-04       Impact factor: 3.445

10.  Co-occurring Hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care.

Authors:  Diana L Sylvestre; Jennifer M Loftis; Peter Hauser; Sander Genser; Helen Cesari; Nicolette Borek; Thomas F Kresina; Leonard Seeff; Henry Francis
Journal:  J Urban Health       Date:  2004-12       Impact factor: 3.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.